Access Investment Management LLC Sells 5,349 Shares of United Therapeutics Corporation $UTHR

Access Investment Management LLC lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 71.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,171 shares of the biotechnology company’s stock after selling 5,349 shares during the quarter. Access Investment Management LLC’s holdings in United Therapeutics were worth $1,287,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of UTHR. Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC increased its position in United Therapeutics by 77.3% during the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia increased its stake in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,921,276.08. This represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 502,833 shares of company stock worth $279,377,162. 8.60% of the stock is currently owned by insiders.

United Therapeutics Stock Down 1.5%

United Therapeutics stock opened at $517.71 on Friday. The business has a 50-day simple moving average of $543.63 and a 200 day simple moving average of $532.44. The stock has a market cap of $21.98 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 1.76 and a beta of 0.58. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the business earned $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of several analyst reports. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $648.33.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.